
Yahoo · 17 de oct de 2026
An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&P 500 over the…
Merck & Co. Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Últimos 225 días · 12/11/25 — 15/10/26
+75.17%
Precio
$ 47.200
Var. %
-0,13%
Volumen operado
1.042
Precio MRK
US$ 146,00
Teórico (precio / ratio)
MRK ÷ 5
US$ 29,20
Sí, existe el CEDEAR de MRK (Merck & Co. Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es MRK.
El ticker del CEDEAR de Merck & Co. Inc. en Argentina es MRK. La acción subyacente cotiza en NYSE con el símbolo MRK.
El CEDEAR MRK tiene un ratio de 5:1. Eso significa que 5 CEDEARs equivalen a 1 acción de MRK.
El CEDEAR MRK cotiza hoy a $ 47.200 en pesos argentinos, con una variación diaria de -0,13%.

Yahoo · 17 de oct de 2026
An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&P 500 over the…

Yahoo · 17 de oct de 2026
Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacing the 1.9%…

Yahoo · 17 de oct de 2026
Gilead Sciences (GILD) built its foundation on HIV treatment. Biktarvy alone accounted for $14.3 billion of the company's $29.4 billion in fiscal 2025 revenue.…
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 31,06
vs teórico
+6,37%
Cotización MEP implícita
$ 1.519,64
Cotización
US$ 29,08
vs teórico
-0,41%
Cotización Cable implícita
$ 1.623,11
La acción subyacente MRK (Merck & Co. Inc.) cotiza a US$ 146,00 en su mercado de origen (NYSE).
El precio teórico del CEDEAR MRK se calcula dividiendo el precio de MRK por el ratio (5). Hoy resulta en US$ 29,20.
En BYMA podés operar MRK en pesos, MRKD en dólar MEP y MRKC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR MRK en pesos argentinos, con datos de data912.

Yahoo · 17 de oct de 2026
Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to the S&P 5…

Yahoo · 16 de oct de 2026
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.

Yahoo · 16 de oct de 2026
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.

Yahoo · 16 de oct de 2026
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a col…

Yahoo · 16 de oct de 2026
AbbVie Inc. (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) have something important in common that is important for investors, which is that both must demonstrate…
Noticias vía Finnhub